2026 Q2 - tulosraportti
81 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,50%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 | - | - | ||
| 1 | - | - | ||
| 18 | - | - | ||
| 218 | - | - | ||
| 324 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·4 t sittenYes, it's not like things have really moved forward for the company since they ousted Lars Jørgensen😂 Even though he spoke dænglish, he probably knew something they are now unable to do.
Have you considered what the consequences would have been today if Mr. Jørgensen had not been dismissed? Drug development is not a quick fix where you just replace the CEO and expect results overnight. It takes years to develop new drugs, and the competitors are not standing still either. The time since 2024/2025 has certainly shown that. Novo Nordisk also had to lay off around 9,000 employees in 2025, which is planned to provide savings of approx. 8-9 billion DKK annually. That is hardly a sign that everything was running perfectly under Mr. Jørgensen. But neither is it proof that one specific CEO could have solved all the challenges. When they chose to dismiss Mr. Jørgensen, Novo was already in reverse and there was no trust that Mr. Jørgensen could turn the ship around. It certainly takes something to dismiss the CEO of the country's largest company. It can only be an expression of the fact that there was no trust whatsoever in the forward-looking strategy under Mr. Jørgensen's leadership. It is fair to discuss whether the current management has made the right decisions and whether Mr. Jørgensen could have done something differently. But to conclude that everything went better under him solely because subsequent developments have been disappointing is wide of the mark. I simply dare not think about the consequences if they had not been ready for the launch of Wegovy in the US in January. And I hardly think Mr. Jørgensen was ready. Furthermore, it is probably a bit controversial to say the following. But the fact that there are employees in Novo who become offended when the CEO addresses a certain culture of complacency testifies, in my opinion, to the fact that the CEO is touching a raw nerve. Novo no longer sells on the basis of their image.
·1 päivä sitten · MuokattuWhat is Novo's Public Relations department actually doing. I find it a pity and a shame that they don't have a more American approach to new initiatives and groundbreaking trials. Sell yourselves big, unlike old innovations you have now entered the fast lane and your market shares are now also about the general market with products for the masses. There is no room for the Law of Jante here.. The stock market is American in all its understanding, - purchases are made from those who are heard and those who sell themselves best. Get that department up from the basement now. I am not Pro-American in any way, quite the contrary, but the new miracle remedies are not just for health, it is also about vanity and it is bought by people driven by emotions. When competitors lay it on thick - then you have to keep up. I think people at Novo fear making a misstep, but nothing ventured, nothing gained. And sell yourselves on being Danish - we actually have a good reputation out there in the big wide world. Which is not so big anymore. It is also humans sitting behind the large pension funds, hedge funds and institutions. Those who start the snowball. Can we please see that Novo truck in the Christmas commercials (ref: Coca Cola ) (irony may occur)
- ·1 päivä sittenNovo Nordisks Awiqli® får FDA-godkendelse som den første og eneste insulin til dosering én gang om ugen til børn fra 10 år med type 2-diabetes - Awiqli® giver børn fra 10 år et alternativ til basalinsulin med ugentlig dosering, hvilket reducerer antallet af basale insulininjektioner fra syv gange om ugen til én gang om ugen. - **Forekomsten af type 2-diabetes blandt børn og unge fortsætter med at stige.**² Awiqli® kan bidrage til at mindske de praktiske barrierer forbundet med daglige injektioner af basalinsulin og give familier adgang til en mere individuelt tilpasset behandling. - Godkendelsen af Awiqli® afspejler Novo Nordisks fortsatte indsats for at fremme innovation i sundhedsvæsenet og styrke støtten til mennesker, der lever med diabetes, samt deres pårørende og omsorgspersoner.
Stockraider only wants to argue and nothing else, doesn't contribute anything at all! 
·1 päivä sittenNovo after closing time USA 260.19 kr- ·1 päivä sittenIt is sort of like Groundhog day keeping up with things in here regarding Novo. There are 3 teams in here. Those who grasp at every straw to convince themselves that now it is turning around. As if writing about positive statements helps lift the share price along. Sorry to say it friends, your comments do not move 4.6 billion shares in any direction. Then there are You who lie in wait and just wait for the price to drop so you can hunt down your compatriots and condescendingly comment that now the price is heading down to the 200s which you know it is going down to. You do not know anything about what the right price is. None of us do. You simply read what the analysts think it should be and then reproduce everything you hear out there. And then there are all the rest of us who know well that the price is controlled by greater forces. We can simply get in the wagon and hope that tomorrow reveals that the powers will now move the money over here. Common among all 3 groups is that many of us have lost a lot of money on Novo, we just have different ways of dealing with it.. All of it is reflected in powerlessness, which manifests differently in humans.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
81 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,50%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·4 t sittenYes, it's not like things have really moved forward for the company since they ousted Lars Jørgensen😂 Even though he spoke dænglish, he probably knew something they are now unable to do.Have you considered what the consequences would have been today if Mr. Jørgensen had not been dismissed? Drug development is not a quick fix where you just replace the CEO and expect results overnight. It takes years to develop new drugs, and the competitors are not standing still either. The time since 2024/2025 has certainly shown that. Novo Nordisk also had to lay off around 9,000 employees in 2025, which is planned to provide savings of approx. 8-9 billion DKK annually. That is hardly a sign that everything was running perfectly under Mr. Jørgensen. But neither is it proof that one specific CEO could have solved all the challenges. When they chose to dismiss Mr. Jørgensen, Novo was already in reverse and there was no trust that Mr. Jørgensen could turn the ship around. It certainly takes something to dismiss the CEO of the country's largest company. It can only be an expression of the fact that there was no trust whatsoever in the forward-looking strategy under Mr. Jørgensen's leadership. It is fair to discuss whether the current management has made the right decisions and whether Mr. Jørgensen could have done something differently. But to conclude that everything went better under him solely because subsequent developments have been disappointing is wide of the mark. I simply dare not think about the consequences if they had not been ready for the launch of Wegovy in the US in January. And I hardly think Mr. Jørgensen was ready. Furthermore, it is probably a bit controversial to say the following. But the fact that there are employees in Novo who become offended when the CEO addresses a certain culture of complacency testifies, in my opinion, to the fact that the CEO is touching a raw nerve. Novo no longer sells on the basis of their image.
- ·1 päivä sitten · MuokattuWhat is Novo's Public Relations department actually doing. I find it a pity and a shame that they don't have a more American approach to new initiatives and groundbreaking trials. Sell yourselves big, unlike old innovations you have now entered the fast lane and your market shares are now also about the general market with products for the masses. There is no room for the Law of Jante here.. The stock market is American in all its understanding, - purchases are made from those who are heard and those who sell themselves best. Get that department up from the basement now. I am not Pro-American in any way, quite the contrary, but the new miracle remedies are not just for health, it is also about vanity and it is bought by people driven by emotions. When competitors lay it on thick - then you have to keep up. I think people at Novo fear making a misstep, but nothing ventured, nothing gained. And sell yourselves on being Danish - we actually have a good reputation out there in the big wide world. Which is not so big anymore. It is also humans sitting behind the large pension funds, hedge funds and institutions. Those who start the snowball. Can we please see that Novo truck in the Christmas commercials (ref: Coca Cola ) (irony may occur)
- ·1 päivä sittenNovo Nordisks Awiqli® får FDA-godkendelse som den første og eneste insulin til dosering én gang om ugen til børn fra 10 år med type 2-diabetes - Awiqli® giver børn fra 10 år et alternativ til basalinsulin med ugentlig dosering, hvilket reducerer antallet af basale insulininjektioner fra syv gange om ugen til én gang om ugen. - **Forekomsten af type 2-diabetes blandt børn og unge fortsætter med at stige.**² Awiqli® kan bidrage til at mindske de praktiske barrierer forbundet med daglige injektioner af basalinsulin og give familier adgang til en mere individuelt tilpasset behandling. - Godkendelsen af Awiqli® afspejler Novo Nordisks fortsatte indsats for at fremme innovation i sundhedsvæsenet og styrke støtten til mennesker, der lever med diabetes, samt deres pårørende og omsorgspersoner.Stockraider only wants to argue and nothing else, doesn't contribute anything at all!
- ·1 päivä sittenNovo after closing time USA 260.19 kr
- ·1 päivä sittenIt is sort of like Groundhog day keeping up with things in here regarding Novo. There are 3 teams in here. Those who grasp at every straw to convince themselves that now it is turning around. As if writing about positive statements helps lift the share price along. Sorry to say it friends, your comments do not move 4.6 billion shares in any direction. Then there are You who lie in wait and just wait for the price to drop so you can hunt down your compatriots and condescendingly comment that now the price is heading down to the 200s which you know it is going down to. You do not know anything about what the right price is. None of us do. You simply read what the analysts think it should be and then reproduce everything you hear out there. And then there are all the rest of us who know well that the price is controlled by greater forces. We can simply get in the wagon and hope that tomorrow reveals that the powers will now move the money over here. Common among all 3 groups is that many of us have lost a lot of money on Novo, we just have different ways of dealing with it.. All of it is reflected in powerlessness, which manifests differently in humans.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 | - | - | ||
| 1 | - | - | ||
| 18 | - | - | ||
| 218 | - | - | ||
| 324 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
81 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
3,75 DKK/osake
Viimeisin osinko
4,50%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·4 t sittenYes, it's not like things have really moved forward for the company since they ousted Lars Jørgensen😂 Even though he spoke dænglish, he probably knew something they are now unable to do.Have you considered what the consequences would have been today if Mr. Jørgensen had not been dismissed? Drug development is not a quick fix where you just replace the CEO and expect results overnight. It takes years to develop new drugs, and the competitors are not standing still either. The time since 2024/2025 has certainly shown that. Novo Nordisk also had to lay off around 9,000 employees in 2025, which is planned to provide savings of approx. 8-9 billion DKK annually. That is hardly a sign that everything was running perfectly under Mr. Jørgensen. But neither is it proof that one specific CEO could have solved all the challenges. When they chose to dismiss Mr. Jørgensen, Novo was already in reverse and there was no trust that Mr. Jørgensen could turn the ship around. It certainly takes something to dismiss the CEO of the country's largest company. It can only be an expression of the fact that there was no trust whatsoever in the forward-looking strategy under Mr. Jørgensen's leadership. It is fair to discuss whether the current management has made the right decisions and whether Mr. Jørgensen could have done something differently. But to conclude that everything went better under him solely because subsequent developments have been disappointing is wide of the mark. I simply dare not think about the consequences if they had not been ready for the launch of Wegovy in the US in January. And I hardly think Mr. Jørgensen was ready. Furthermore, it is probably a bit controversial to say the following. But the fact that there are employees in Novo who become offended when the CEO addresses a certain culture of complacency testifies, in my opinion, to the fact that the CEO is touching a raw nerve. Novo no longer sells on the basis of their image.
- ·1 päivä sitten · MuokattuWhat is Novo's Public Relations department actually doing. I find it a pity and a shame that they don't have a more American approach to new initiatives and groundbreaking trials. Sell yourselves big, unlike old innovations you have now entered the fast lane and your market shares are now also about the general market with products for the masses. There is no room for the Law of Jante here.. The stock market is American in all its understanding, - purchases are made from those who are heard and those who sell themselves best. Get that department up from the basement now. I am not Pro-American in any way, quite the contrary, but the new miracle remedies are not just for health, it is also about vanity and it is bought by people driven by emotions. When competitors lay it on thick - then you have to keep up. I think people at Novo fear making a misstep, but nothing ventured, nothing gained. And sell yourselves on being Danish - we actually have a good reputation out there in the big wide world. Which is not so big anymore. It is also humans sitting behind the large pension funds, hedge funds and institutions. Those who start the snowball. Can we please see that Novo truck in the Christmas commercials (ref: Coca Cola ) (irony may occur)
- ·1 päivä sittenNovo Nordisks Awiqli® får FDA-godkendelse som den første og eneste insulin til dosering én gang om ugen til børn fra 10 år med type 2-diabetes - Awiqli® giver børn fra 10 år et alternativ til basalinsulin med ugentlig dosering, hvilket reducerer antallet af basale insulininjektioner fra syv gange om ugen til én gang om ugen. - **Forekomsten af type 2-diabetes blandt børn og unge fortsætter med at stige.**² Awiqli® kan bidrage til at mindske de praktiske barrierer forbundet med daglige injektioner af basalinsulin og give familier adgang til en mere individuelt tilpasset behandling. - Godkendelsen af Awiqli® afspejler Novo Nordisks fortsatte indsats for at fremme innovation i sundhedsvæsenet og styrke støtten til mennesker, der lever med diabetes, samt deres pårørende og omsorgspersoner.Stockraider only wants to argue and nothing else, doesn't contribute anything at all!
- ·1 päivä sittenNovo after closing time USA 260.19 kr
- ·1 päivä sittenIt is sort of like Groundhog day keeping up with things in here regarding Novo. There are 3 teams in here. Those who grasp at every straw to convince themselves that now it is turning around. As if writing about positive statements helps lift the share price along. Sorry to say it friends, your comments do not move 4.6 billion shares in any direction. Then there are You who lie in wait and just wait for the price to drop so you can hunt down your compatriots and condescendingly comment that now the price is heading down to the 200s which you know it is going down to. You do not know anything about what the right price is. None of us do. You simply read what the analysts think it should be and then reproduce everything you hear out there. And then there are all the rest of us who know well that the price is controlled by greater forces. We can simply get in the wagon and hope that tomorrow reveals that the powers will now move the money over here. Common among all 3 groups is that many of us have lost a lot of money on Novo, we just have different ways of dealing with it.. All of it is reflected in powerlessness, which manifests differently in humans.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 | - | - | ||
| 1 | - | - | ||
| 18 | - | - | ||
| 218 | - | - | ||
| 324 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt